NEW YORK, Oct. 6, 2022 /PRNewswire/ -- The cytomegalovirus (CMV) therapeutics market is expected to grow by USD 332.21 million during 2021-2026 according to the latest market research report by Technavio. As per Technavio, the reformulation of drugs will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other significant trends and market drivers that will influence market growth.

North America will account for 37% of market growth. Cytomegalovirus (CMV) treatments are primarily sold in the US and Canada North America. Compared to the rest of the world, this region's market will increase more quickly (ROW). The cytomegalovirus (CMV) therapeutics market will increase in North America over the forecast period due to the high sales of authorized therapies and the considerable prevalence of various kinds of CMV in nations like the US. Request Free Sample Report.

• Route of administration
• Oral
• Parenteral
• Others
• Geography 
• North America
• Europe
• Asia
• Rest of World (ROW)

The oral sector will significantly increase its market share for cytomegalovirus (CMV) therapies during the anticipated period. In the upcoming years, the presence of F. Hoffmann-La Roche and its cutting-edge medication VALCYTE will fuel market expansion in this niche. The US FDA later granted it marketing permission for the prevention of CMV in patients who have undergone kidney, heart, or kidney-pancreas transplantation after it first gained the necessary approval for the treatment of CMV retinitis in patients with acquired AIDS. Buy Sample Report.

The expanding risk factors for CMV are one of the major reasons boosting the global cytomegalovirus (CMV) treatments market. CMV is more prevalent in populations with inadequate immunity, such as those living with HIV. Although the incidence rate has decreased, there is still a significant unmet market demand because of the high prevalence, which is thought to affect around 37 million people globally, and the paucity of licensed medicines.

The danger of CMV infection is further increased by the rising number of hematopoietic stem cell transplant (HSCT) procedures performed for diverse causes. Another known risk factor for CMV is chemotherapy. During the anticipated period, all of these elements are anticipated to fuel market expansion. Download Free Sample Report.

Another major market trend for CMV therapies that are anticipated to have a favorable effect on the sector throughout the forecast period is the reformulation of medications. Vendors are creating medications in multiple forms in order to offer treatment options and guarantee the high efficacy of their products. 

• Astellas Pharma Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Chimerix Inc.
• Clinigen Group Plc
• Exela Pharma Sciences LLC
• F. Hoffmann La Roche Ltd.
• Fortress Biotech Inc.
• Fresenius SE and Co. KGaA
• Genentech Inc.
• Gilead Sciences Inc.
• Merck and Co. Inc.

Table of Contents

1 Executive Summary

• 1.1 Market Overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Route of Administration

• 5.1 Market segments 
• Exhibit 24: Chart on Route of Administration - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Route of Administration - Market share 2021-2026 (%)

• 5.2 Comparison by Route of Administration 
• Exhibit 26: Chart on Comparison by Route of Administration
• Exhibit 27: Data Table on Comparison by Route of Administration

• 5.3 Oral - Market size and forecast 2021-2026
• Exhibit 28: Chart on Oral - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Oral - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Oral - Year-over-year growth 2021-2026 (%)

• 5.4 Parenteral - Market size and forecast 2021-2026
• Exhibit 32: Chart on Parenteral - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Parenteral - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Parenteral - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Parenteral - Year-over-year growth 2021-2026 (%)

• 5.5 Others - Market size and forecast 2021-2026
• Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Route of Administration
• Exhibit 40: Market opportunity by Route of Administration ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Denmark - Market size and forecast 2021-2026
• Exhibit 66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 India - Market size and forecast 2021-2026
• Exhibit 78: Chart on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on India - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on India - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 88: Matrix on vendor position and classification

• 10.3 AstraZeneca Plc 
• Exhibit 89: AstraZeneca Plc - Overview
• Exhibit 90: AstraZeneca Plc - Product / Service
• Exhibit 91: AstraZeneca Plc - Key news
• Exhibit 92: AstraZeneca Plc - Key offerings

• 10.4 Bausch Health Companies Inc. 
• Exhibit 93: Bausch Health Companies Inc. - Overview
• Exhibit 94: Bausch Health Companies Inc. - Business segments
• Exhibit 95: Bausch Health Companies Inc. - Key news
• Exhibit 96: Bausch Health Companies Inc. - Key offerings
• Exhibit 97: Bausch Health Companies Inc. - Segment focus

• 10.5 Chimerix Inc. 
• Exhibit 98: Chimerix Inc. - Overview
• Exhibit 99: Chimerix Inc. - Product / Service
• Exhibit 100: Chimerix Inc. - Key offerings

• 10.6 Exela Pharma Sciences LLC 
• Exhibit 101: Exela Pharma Sciences LLC - Overview
• Exhibit 102: Exela Pharma Sciences LLC - Product / Service
• Exhibit 103: Exela Pharma Sciences LLC - Key offerings

• 10.7 F. Hoffmann La Roche Ltd. 
• Exhibit 104: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 105: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 106: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 107: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 108: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Fortress Biotech Inc. 
• Exhibit 109: Fortress Biotech Inc. - Overview
• Exhibit 110: Fortress Biotech Inc. - Business segments
• Exhibit 111: Fortress Biotech Inc. - Key offerings
• Exhibit 112: Fortress Biotech Inc. - Segment focus

• 10.9 Gilead Sciences Inc. 
• Exhibit 113: Gilead Sciences Inc. - Overview
• Exhibit 114: Gilead Sciences Inc. - Product / Service
• Exhibit 115: Gilead Sciences Inc. - Key news
• Exhibit 116: Gilead Sciences Inc. - Key offerings

• 10.10 Merck and Co. Inc. 
• Exhibit 117: Merck and Co. Inc. - Overview
• Exhibit 118: Merck and Co. Inc. - Business segments
• Exhibit 119: Merck and Co. Inc. - Key news
• Exhibit 120: Merck and Co. Inc. - Key offerings
• Exhibit 121: Merck and Co. Inc. - Segment focus

• 10.11 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 122: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 123: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 124: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 125: Takeda Pharmaceutical Co. Ltd. - Key offerings

• 10.12 Teva Pharmaceutical Industries Ltd. 
• Exhibit 126: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 127: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 128: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 129: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 130: Teva Pharmaceutical Industries Ltd. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 131: Inclusions checklist
• Exhibit 132: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 133: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 134: Research methodology
• Exhibit 135: Validation techniques employed for market sizing
• Exhibit 136: Information sources

• 11.5 List of abbreviations 
• Exhibit 137: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytomegalovirus-cmv-therapeutics-market-to-grow-by-usd-332-21-mn-in-2026--growing-risk-factors-for-cmv-to-boost-the-market-growth---technavio-301641144.html

SOURCE Technavio